EOLS — Evolus Inc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
$9.08
-$0.01 (-0.11%)
Evolus Inc (EOLS) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by David Moatazedi, based in 520 Newport Center Drive, Newport Beach, CA, United States, 92660, with about 372 employees. Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Latest reported EOLS revenue for 2025-09-30 was $69.0M. Net income was -$15.7M. Revenue was down 0.6% from 2025-06-30 to 2025-09-30. EOLS currently screens at market cap $597.0M.
Use this EOLS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the EOLS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the EOLS SEC filings page. Lician reads the product cache first so this HTML stays unique to Evolus Inc even when a live quote feed is slow.
About Evolus Inc
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
EOLS Key Statistics
Market Cap
$597.04M
Volume
938,572
Previous Close
$8.97
Day Range
$8.86 – $9.08
EPS
-$0.81
Revenue
$266.27M
Net Income
-$50.42M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+31.8%
Profit Margin
-18.9%
Employees
372
EOLS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $266.27M | $202.09M | $148.62M | $99.67M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$50.42M | -$61.69M | -$74.41M | -$46.81M |
| EPS (Diluted) | -$0.81 | -$1.08 | -$1.33 | -$0.94 |
Total Assets
$232.57M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$86.95M
Operating Cash Flow
-$18.00M
Free Cash Flow
$0.00
Evolus Inc Company Information
- President, CEO & Director
- David Moatazedi
- Headquarters
- 520 Newport Center Drive, Newport Beach, CA, United States, 92660
- Website
- www.evolus.com
- Phone
- 949 284 4555
- IPO / Founded
- 2018-02-08
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic